<DOC>
	<DOCNO>NCT00048282</DOCNO>
	<brief_summary>The purpose study provide researcher information help prepare future study test efficacy two anti-HIV vaginal gel . This study also estimate likely people live certain area become infected HIV infection pass sex .</brief_summary>
	<brief_title>HIV Prevention Preparedness Study</brief_title>
	<detailed_description>This study design prepare implementation second study , HPTN 035 : A Phase II/III Safety Effectiveness Study Vaginal Microbicides BufferGel PRO 2000/5 Gel ( P ) Prevention HIV Infection Women . HPTN 035 require average HIV seroincidence rate 5-6 percent among enrolled participant . The primary objective present study estimate rate HIV seroincidence among woman target inclusion HPTN 035 . Women enrol study 6 12 month . Study visit take place monthly . At visit , participant complete medical/menstrual history undergo pregnancy test . Each quarter , participant undergo structure interview sexual practice receive HIV STD test , education , counsel . Participants also undergo pelvic exam wet mount test bacterial vaginosis , candidiasis , trichomoniasis . Colposcopic evaluation perform select site . Pap smear perform site capacity expertise prepare interpret smear provide appropriate follow-up care participant abnormal result .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Inclusion criterion : Sexually active ( defined vaginal intercourse least 3 month prior screen ) . HIVuninfected screening . Able willing provide adequate locator information study retention purpose . Exclusion criterion : History adverse reaction latex . Nontherapeutic injection drug use 12 month prior screen . Vaginal intercourse average 2 time per day 2 week prior screen . Plans travel away study site 3 consecutive month next 12 month . Plans relocate away study site next 12 month . Pregnancy plan become pregnant next 12 month . Pregnancy within 42 day prior enrollment . Enrollment study vaginallyapplied product . Clinically apparent pelvic exam find involve deep epithelial disruption . Diagnosis current STD and/or reproductive tract infection require treatment . Conditions would preclude provision inform consent , make participation study unsafe , complicate interpretation study outcome data , otherwise interfere achieve study objective .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2006</verification_date>
	<keyword>Incidence</keyword>
	<keyword>HIV Seroprevalence</keyword>
	<keyword>Vagina</keyword>
	<keyword>Anti-Infective Agents</keyword>
	<keyword>Administration , Topical</keyword>
	<keyword>Gels</keyword>
	<keyword>HIV Seronegativity</keyword>
</DOC>